HOME >> BIOLOGY >> NEWS
Innovative method for gene therapy of heart disease shows promise in animal studies

Philadelphia, Pa. Heart disease patients may someday receive a dose of gene therapy that would protect injured coronary arteries from further damage and possibly even treat the underlying heart disease. The genes would be delivered to artery walls by stents, the tiny metal scaffolds that are now implanted in diseased arteries to hold the vessels open for improved blood flow.

In cell cultures and in pigs, a team led by a researcher from The Childrens Hospital of Philadelphia showed that genes in DNA added to the stents were transferred into cells on the artery wall. The study appeared in the November issue of the journal Nature Biotechnology.

"This is the first example of gene transfer in an animal model using stents for DNA delivery," said Robert J. Levy, M.D., director of the Pediatric Cardiology Research Laboratory at The Childrens Hospital of Philadelphia. "The technique has major implications for treating coronary artery disease with gene therapy."

Stents are commonly used in angioplasty procedures for partially blocked coronary arteries. After a small balloon is inserted through a catheter and inflated to widen a narrowed artery (the angioplasty procedure), an expandable wire scaffolding (the stent) is left in the artery to keep it open. However, in approximately 30 percent of patients, stents injure the artery, causing cells to grow back within a few months, often forming new obstructions.

The gene delivery technique employed by Dr. Levys team would release a gene or combination of genes that can help control blood vessel damage by inhibiting cell growth in the artery walls. "Further research is needed to identify genes that would have the most beneficial effect," said Dr. Levy, "but this study in animals shows that the gene delivery technique is possible."

Delivery is a crucial problem in any gene therapy approach. Unlike other approaches that uses viruses as delivery vehicles to carry genes into the body, Dr. Levys group uses DNA w
'"/>

Contact: Maria Stearns
stearnsm@email.chop.edu
215-590-4091
Children's Hospital of Philadelphia
7-Nov-2000


Page: 1 2

Related biology news :

1. Innovative ceramic-on-metal hip replacements to undergo clinical trials
2. Innovative efforts target epigenetics, molecular imaging
3. Innovative self healing bandage to help diabetics
4. Innovative shuttle bus debuts in Washington, D.C.
5. Innovative research with pythons offers new insights into the bodys digestive processes
6. Vaccination following spinal cord injury: Innovative Weizmann Institute approach limits paralysis
7. Innovative Process To Benefit Ground Water Clean-Up
8. Exotic Species, Migratory Birds, Sea Level Rise, Wetlands, And Contaminants...USGS Scientists Discuss Innovative Chesapeake Bay Restoration Studies
9. UF Researchers Innovative Fence Helps Control Sand Flies
10. ACS Conference Brief: An Innovative Molecular Assembly
11. Cystic Fibrosis Foundation Launches Innovative Therapeutics Development Centers

Post Your Comments:
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
(Date:5/20/2015)... , May 20, 2015 Veracyte, ... preliminary data demonstrating the ability of the company,s ... (IPF) from other interstitial lung diseases (ILDs) using ... classifier,s potential to help thousands of patients avoid ... in IPF diagnosis – a frequent challenge for ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
Cached News: